plushcare glp-1 Review: Telemedicine Providers Compared – PlexusDx plushcare glp 1 GLP-1 Medications:

In the safety profile, pooling three studies with 640 patients, most adverse events associated with retatrutide were mild and did not result in treatment discontinuation

The growing prevalence of metabolic disease, CKD, and ASCVD have prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks, particularly within the framework of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, irrespective of diabetic status

So the drug is there, but its full effect isnt

Within a week of starting a GLP-1, everything changed

The best factors to look at are effectiveness, frequency of dosing and side effect profiles

Its diabetes drug Mounjaro (tirzepatide, a GLP-1/GIP dual agonist) showed superior weight-loss to Wegovy (about 20% average body weight reduction vs ~14% in a head-to-head trial) ( [18] ), and its obesity-specific formulation Zepbound rapidly gained market share (reaching ~$3.6B sales in Q3 2025 ( [19] ))